https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Thyroid disease in chronic hepatitis C Infection and interferon-α based therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13683 Wed 11 Apr 2018 13:31:00 AEST ]]> The natural history of interferon-α induced thyroiditis in chronic hepatitis c patients: a long term study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15682 Wed 11 Apr 2018 11:23:52 AEST ]]> Peginterferon and ribavirin for hepatitis C (letter) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4549 Wed 11 Apr 2018 10:25:52 AEST ]]> Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46208 Mon 14 Nov 2022 11:43:52 AEDT ]]> Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19984 Mon 08 Apr 2019 11:09:34 AEST ]]> Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42242 90% of patients exhibiting concentrations within the defined target range throughout the entire treatment course. Additional work to formally establish target therapeutic concentrations is required; however, this study provides a valuable first step in determining optimal ribavirin treatment regimens for paramyxovirus infections in the lung transplant population.]]> Fri 19 Aug 2022 11:56:24 AEST ]]>